Table 4 The FQPA factor determinations for non-dietary exposures
FQPA factor for incidental oral exposure | FQPA factor for dermal exposure | FQPA factor for inhalation exposure | |
|---|---|---|---|
Number of pesticides for which an FQPA factor was assigned for this exposure scenario | 27 | 16 | 27 |
Number of pesticides for which this exposure scenario has an FQPA factor greater than 1X | 4 | 5 | 11 |
Percentage of pesticides for which this exposure scenario has an FQPA factor greater than 1X | 15% | 31% | 41% |
Which pesticides have an FQPA factor greater than 1X for this scenario | Chlorpropham, glufosinate, tebuconazole, thiophanate-methyl | Chlorpropham, glufosinate, iprodione, tebuconazole, thiophanate-methyl | 2,4-D, chlorothalonil, chlorpropham, cyprodinil, dicamba BAPMA salt, glufosinate, iprodione, tebuconazole, thiabendazole, thiophanate-methyl, trifloxystrobin |
1,3-Dichloropropene | N/A | N/A | 1X (4 scenarios for different exposure durations: acute, short-term; intermediate-term; and long-term) |
2,4-D | 1X (1 scenario for short- and intermediate-term) | N/A | 10X (1 scenario for all exposure durations) |
Acetamiprid | 1X (2 scenarios for different exposure durations: short- and intermediate-term; and long-term) | 1X (2 scenarios for different exposure durations: short- and intermediate-term; and long-term) | 1X (1 scenario for short- and intermediate-term) |
Azoxystrobin | 1X (1 scenario for short- and intermediate-term) | N/A | N/A |
Boscalid | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) |
Captan | 1X (1 scenario for short-term) | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) |
Chlorothalonil | 1X (2 scenarios for different exposure durations: short-term; and intermediate-term) | N/A | 3X and 30X (2 scenarios for different exposure durations: acute inhalation with 3X FQPA factor; and short- and intermediate-term inhalation with 30X FQPA factor) |
Chlorpropham | 10X (1 scenario for short- and intermediate-term) | 10X (1 scenario for short- and intermediate-term) | 10X (1 scenario for short- and intermediate-term) |
Clothianidin | 1X (1 scenario for short-term) | 1X (1 scenario for all durations) | 1X (1 scenario for all durations) |
Cyprodinil | 1X (1 scenario for short-term) | N/A | 10X (1 scenario for short- and intermediate-term) |
Dicamba | 1X (1 scenario for short- and intermediate-term) | N/A | 2 scenarios: 1X for short-, intermediate- and long-term inhalation scenario for dicamba acid; 10X for short-, intermediate- and long-term inhalation scenario for dicamba BAPMA salt |
Dimethomorph | 1X (1 scenario for short-term) | N/A | N/A |
Fenhexamid | 1X (1 scenario for short- and intermediate-term) | N/A | 1X (1 scenario for short- and intermediate-term) |
Fludioxonil | 1X (1 scenario for short- and intermediate-term) | N/A | 1X (1 scenario for short- and intermediate-term) |
Fluopicolide | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) |
Glufosinate | 10X (1 scenario for short- and intermediate-term) | 10X (1 scenario for short- and intermediate-term) | 10X (1 scenario for acute, short- and intermediate-term) |
Glyphosate | 1X (1 scenario for short- and intermediate-term) | N/A | N/A |
Imidacloprid | 1X (1 scenario for all durations) | 1X (1 scenario for all durations) | 1X (1 scenario for all durations) |
Iprodione | N/A | 10X (1 scenario for dermal and inhalation, short- and intermediate-term) | |
Metalaxyl/Mefenoxam | 1X (1 scenario for short- and intermediate-term) | N/A | 1X (1 scenario for short- and intermediate-term) |
Metolachlor | 1X (1 scenario for short-term) | 1X (1 scenario for short- and intermediate-term exposure for children) | 1X (1 scenario for short- and intermediate-term) |
Paraquat | 1X (1 scenario for short-term) | 1X (1 scenario for short-term) | 1X (1 scenario for short-term) |
Pendimethalin | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) |
Pyraclostrobin | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) |
Pyrimethanil | N/A | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) |
Spinetoram | 1X (1 scenario for short- and intermediate-term) | N/A | 1X (1 scenario for short- and intermediate-term) |
Tebuconazole | 3X (1 scenario for short-term) | 3X (1 scenario for short-term) | 3X (1 scenario for short-term) |
Thiabendazole | 1X (2 scenarios, for short- and intermediate-term exposure for children and for short- and intermediate-term exposure for adults) | N/A | 10X (1 scenario for short- and intermediate-term) |
Thiophanate-methyl | 3X (1 scenario for short- and intermediate-term) | 3X (2 scenarios for short- and intermediate-term, and for long-term exposures) | 3X (2 scenarios for short- and intermediate-term, and for long-term exposures) |
Trifloxystrobin | 1X (1 scenario for short-term) | N/A | 10X (1 scenario for all durations) |